Table displaying (1) the accumulated number of visits during the follow-up period where patients were in inflammatory remission, stratified by treatment targets, (2) the total number of new DMARD starts during these visits, (3) the average rate of new DMARD starts per visits and (4) the rate ratio comparing visits with patients in inflammatory remission who failed to reach, versus reached, the treatment targets
| Visits with patients in inflammatory remission, stratified by treatment targets: | Total no of visits during follow-up period, 3–24 months | Total no of DMARD starts during follow-up, 3–24 months | Rate of DMARD starts per visit, mean (SD) | RR (95% CI) |
| DAS28 non-remission versus DAS28 remission | 2046 vs 8121 | 405 vs 1307 | 0.22 (0.45) vs 0.16 (0.40) | 1.36 (1.22 to 1.51) |
| DAS28 non-LDA versus DAS28 LDA | 815 vs 9352 | 218 vs 1539 | 0.27 (0.48) vs 0.17 (0.41) | 1.56 (1.35 to 1.80) |
| SDAI non-remission versus SDAI remission | 4676 vs 4861 | 977 vs 660 | 0.21 (0.45) vs 0.14 (0.37) | 1.48 (1.34 to 1.64) |
| SDAI non-LDA versus SDAI LDA | 732 vs 8805 | 221 vs 1416 | 0.30 (0.50) vs 0.16 (0.40) | 1.72 (1.49 to 1.98) |
| Boolean non-remission versus Boolean remission | 6104 vs 4063 | 1211 vs 546 | 0.20 (0.43) vs 0.13 (0.38) | 1.41 (1.28 to 1.56) |
The RRs are analysed by Poisson regression, adjusted for age, sex and year of inclusion in SRQ (2011–2015 vs 2016–2020).
DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; LDA, low disease activity; RR, rate ratio; SDAI, Simplified Disease Activity Index; SRQ, Swedish Rheumatology Quality Register.